Members
 | First name: Francoise Last name: Chau Function: Engineer Position: Occupational health manager Email: francoise.chauinserm.fr |
Research interest
Acting as a research engineer among “IAME “ laboratory allows me to be involved in research studies directed by Agnès Lefort, Victoire de Lastours and Bruno Fantin. We particularly focus our investigations on the impact of antibiotic exposure on the selection of bacterial resistance in experimental foci of infection in animals and in the human microbiota from healthy volunteers, in- and outpatients. I personally developed the technique of flow-cytometry analysis in bacterial cells to investigate antimicrobials activity against bacterial cell wall.
Education
Research training (post doctoral)
2014-present: Engineer University Denis Diderot, IAME U1137
2008-2013: Engineer University Denis Diderot,EA3964
2000-2008: Research Technician University Denis Diderot,EA3964
1994-2000: Research Technician University Denis Diderot, EMI9933
1980-1994: Research Technician University Denis Diderot, INSERM U13
2008-2013: Engineer University Denis Diderot,EA3964
2000-2008: Research Technician University Denis Diderot,EA3964
1994-2000: Research Technician University Denis Diderot, EMI9933
1980-1994: Research Technician University Denis Diderot, INSERM U13
List of the main publications
Soubirou JF, Rossi B, Couffignal C, Ruppé E, Chau F, Massias L, Lepeule R, Mentre F, Fantin B
Activity of temocillin in a murine model of urinary tract infection due to Escherichia coli producing or not producing the ESBL CTX-M-15.
The Journal of Antimicrobial Chemotherapy 2015, 70, 1466–1472.
Lefort A, Chau F, Lepeule R, Dubée V, Kitzis MD, Dion S, Fantin B
Activity of fosfomycin alone or combined with cefoxitin in vitro and in vivo in a murine model of urinary tract infection due to Escherichia coli harbouring CTX-M-15-type extended-spectrum β-lactamase.
International Journal of Antimicrobial Agents 2014, 43, 366-369.
de Lastours V, Bleibtreu A, Chau F, Burdet C, Duval X, Denamur E, Fantin B
Quinolone-resistant Escherichia coli from the faecal microbiota of healthy volunteers after ciprofloxacin exposure are highly adapted to a commensal lifestyle.
The Journal of Antimicrobial Chemotherapy 2014, 69, 761-768.
de Lastours V, Chau F, Roy C, Larroque B, Fantin B
Emergence of quinolone resistance in the microbiota of hospitalized patients treated or not with a fluoroquinolone.
The Journal of Antimicrobial Chemotherapy 2014
Jlili NEH, Réjiba S, Smaoui H, Guillard T, Chau F, Kechrid A, Cambau E
Trend of plasmid-mediated quinolone resistance genes at the Children's Hospital in Tunisia.
Journal of Medical Microbiology 2014, 63, 195-202.
Guillard T, Cambau E, Chau F, Massias L, de Champs C, Fantin B
Ciprofloxacin treatment failure in a murine model of pyelonephritis due to an AAC(6')-Ib-cr-producing Escherichia coli strain susceptible to ciprofloxacin in vitro.
Antimicrobial Agents and Chemotherapy 2013, 57, 5830-5835.
Augustin P, Alsalih G, Launey Y, Delbosc S, Louedec L, Ollivier V, Chau F, Montravers P, Duval X, Michel JB, Meilhac O
Predominant role of host proteases in myocardial damage associated with infectious endocarditis induced by Enterococcus faecalis in a rat model.
Infection and Immunity 2013, 81, 1721–1729.
Lepeule R, Ruppé E, Le P, Massias L, Chau F, Nucci A, Lefort A, Fantin B
Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.
Antimicrobial Agents and Chemotherapy 2012, 56, 1376-1381.
Activity of temocillin in a murine model of urinary tract infection due to Escherichia coli producing or not producing the ESBL CTX-M-15.
The Journal of Antimicrobial Chemotherapy 2015, 70, 1466–1472.
Lefort A, Chau F, Lepeule R, Dubée V, Kitzis MD, Dion S, Fantin B
Activity of fosfomycin alone or combined with cefoxitin in vitro and in vivo in a murine model of urinary tract infection due to Escherichia coli harbouring CTX-M-15-type extended-spectrum β-lactamase.
International Journal of Antimicrobial Agents 2014, 43, 366-369.
de Lastours V, Bleibtreu A, Chau F, Burdet C, Duval X, Denamur E, Fantin B
Quinolone-resistant Escherichia coli from the faecal microbiota of healthy volunteers after ciprofloxacin exposure are highly adapted to a commensal lifestyle.
The Journal of Antimicrobial Chemotherapy 2014, 69, 761-768.
de Lastours V, Chau F, Roy C, Larroque B, Fantin B
Emergence of quinolone resistance in the microbiota of hospitalized patients treated or not with a fluoroquinolone.
The Journal of Antimicrobial Chemotherapy 2014
Jlili NEH, Réjiba S, Smaoui H, Guillard T, Chau F, Kechrid A, Cambau E
Trend of plasmid-mediated quinolone resistance genes at the Children's Hospital in Tunisia.
Journal of Medical Microbiology 2014, 63, 195-202.
Guillard T, Cambau E, Chau F, Massias L, de Champs C, Fantin B
Ciprofloxacin treatment failure in a murine model of pyelonephritis due to an AAC(6')-Ib-cr-producing Escherichia coli strain susceptible to ciprofloxacin in vitro.
Antimicrobial Agents and Chemotherapy 2013, 57, 5830-5835.
Augustin P, Alsalih G, Launey Y, Delbosc S, Louedec L, Ollivier V, Chau F, Montravers P, Duval X, Michel JB, Meilhac O
Predominant role of host proteases in myocardial damage associated with infectious endocarditis induced by Enterococcus faecalis in a rat model.
Infection and Immunity 2013, 81, 1721–1729.
Lepeule R, Ruppé E, Le P, Massias L, Chau F, Nucci A, Lefort A, Fantin B
Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.
Antimicrobial Agents and Chemotherapy 2012, 56, 1376-1381.
Exhaustive list of publications
2022
de Lastours V, El Meouche I, Chau F, Beghain J, Chevret D, Aubert-Frambourg A, Clermont O, Royer G, Bouvet O, Denamur E, Fantin B, CG
Evolution of fluoroquinolone-resistant Escherichia coli in the gut after ciprofloxacin treatment.
International journal of medical microbiology: IJMM 2022, 312, 151548.
Royer G, Ortiz de la Rosa JM, Vuillemin X, Lacombe B, Chau F, Clermont O, Mercier-Darty M, Decousser JW, Ricard JD, Nordmann P, Denamur E, Poirel L
Reduced Chlorhexidine Susceptibility Is Associated with Tetracycline Resistance tet Genes in Clinical Isolates of Escherichia coli.
Antimicrobial Agents and Chemotherapy 2022, 66, e0197221.
2021
Royer G, Poirel L, La Combe B, Clermont O, Chau F, Mercier-Darty M, Denamur E, Nordmann P, Ricard JD, Decousser JW
Lack of association between colistin resistance and chlorhexidine reduced susceptibility in clinical isolates of Escherichia coli.
The Journal of Antimicrobial Chemotherapy 2021, 76, 2736-2737.
Le Menestrel A, Guerin F, Chau F, Massias L, Benchetrit L, Cattoir V, Fantin B, de Lastours V
Activity of the combination of colistin and fosfomycin against NDM-1-producing Escherichia coli with variable levels of susceptibility to colistin and fosfomycin in a murine model of peritonitis.
The Journal of Antimicrobial Chemotherapy 2021, 77, 155-163.
2020
Canovas J, Petitjean G, Chau F, Le Monnier A, Fantin B, Lefort A
Expression of CTX-M-15 limits the efficacy of ceftolozane/tazobactam against Escherichia coli in a high-inoculum murine peritonitis model.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2020, 26, 1416.e5-1416.e9.
Cheminet G, de Lastours V, Poirel L, Chau F, Peoc'h K, Massias L, Fantin B, Nordmann P
Dimercaptosuccinic acid in combination with carbapenems against isogenic strains of Escherichia coli producing or not producing a metallo-β-lactamase in vitro and in murine peritonitis.
The Journal of Antimicrobial Chemotherapy 2020, 75, 3593-3600.
Roujansky A, de Lastours V, Guérin F, Chau F, Cheminet G, Massias L, Cattoir V, Fantin B
Analysis of Paradoxical Efficacy of Carbapenems against Carbapenemase-Producing Escherichia coli in a Murine Model of Lethal Peritonitis.
Antimicrobial Agents and Chemotherapy 2020, 64,
2019
Fantin B, Poujade J, Grégoire N, Chau F, Roujansky A, Kieffer N, Berleur M, Couet W, Nordmann P
The inoculum effect of Escherichia coli expressing mcr-1 or not on colistin activity in a murine model of peritonitis.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2019, 25, 1563.e5-1563.e8.
Alexandre K, Soares A, Chau F, Fantin B, Caron F, Etienne M
Temocillin breakpoints in pyelonephritis: evaluation in a murine model due to ESBL-producing Escherichia coli clinical isolates.
The Journal of Antimicrobial Chemotherapy 2019, 74, 1323-1326.
Cantier M, Sabben C, Adle-Biassette H, Louedec L, Delbosc S, Desilles JP, Journé C, Diallo D, Ou P, Klein I, Chau F, Lefort A, Iung B, Duval X, Olivot JM, Ho-Tin-Noe B, Michel JB, Sonneville R, Mazighi M
Neurologic Complications of Infective Endocarditis: A Joint Model for a Septic Thromboembolism and Inflammatory Small Vessel Disease.
Critical Care Medicine 2019, 47, e685-e692.
Pourbaix A, Guérin F, Burdet C, Massias L, Chau F, Cattoir V, Fantin B
Unexpected Activity of Oral Fosfomycin against Resistant Strains of Escherichia coli in Murine Pyelonephritis.
Antimicrobial Agents and Chemotherapy 2019, 63, e00903-19.
2018
de Lastours V, Goulenok T, Guérin F, Jacquier H, Eyma C, Chau F, Cattoir V, Fantin B
Ceftriaxone promotes the emergence of AmpC-overproducing Enterobacteriaceae in gut microbiota from hospitalized patients.
European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology 2018, 37, 417-421.
Berleur M, Guérin F, Massias L, Chau F, Poujade J, Cattoir V, Fantin B, de Lastours V
Activity of fosfomycin alone or combined with temocillin in vitro and in a murine model of peritonitis due to KPC-3- or OXA-48-producing Escherichia coli.
The Journal of Antimicrobial Chemotherapy 2018, 73, 3074-3080.
2017
de Lastours V, Maugy E, Mathy V, Chau F, Rossi B, Guérin F, Cattoir V, Fantin B, CSG
Ecological impact of ciprofloxacin on commensal enterococci in healthy volunteers.
The Journal of Antimicrobial Chemotherapy 2017, 72, 1574-1580.
Mougari F, Bouziane F, Crockett F, Nessar R, Chau F, Veziris N, Sapriel G, Raskine L, Cambau E
Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies.
Antimicrobial Agents and Chemotherapy 2017, 61,
2016
Bernard J, Armand-Lefèvre L, Luce E, El Mniai A, Chau F, Casalino E, Andremont A, Ruppé E
Impact of a short exposure to levofloxacin on faecal densities and relative abundance of total and quinolone-resistant Enterobacteriaceae.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2016, 22, 646.e1-4.
Jayol A, Janvier F, Guillard T, Chau F, Mérens A, Robert J, Fantin B, Berçot B, Cambau E
qnrA6 genetic environment and quinolone resistance conferred on Proteus mirabilis.
The Journal of Antimicrobial Chemotherapy 2016, 71, 903-908.
Alexandre K, Chau F, Guérin F, Massias L, Lefort A, Cattoir V, Fantin B
Activity of temocillin in a lethal murine model of infection of intra-abdominal origin due to KPC-producing Escherichia coli.
The Journal of Antimicrobial Chemotherapy 2016
de Lastours V, Chopin D, Jacquier H, d'Humieres C, Burdet C, Chau F, Denamur E, Fantin B
Prospective Cohort Study of the Relative Abundance of Extended-Spectrum-Beta-Lactamase-Producing Escherichia coli in the Gut of Patients Admitted to Hospitals.
Antimicrob Agents Chemother 2016, 60, 6941-6944.
2015
Munier AL, de Lastours V, Barbier F, Chau F, Fantin B, Ruimy R
Comparative dynamics of the emergence of fluoroquinolone resistance in staphylococci from the nasal microbiota of patients treated with fluoroquinolones according to their environment.
International Journal of Antimicrobial Agents 2015
Soubirou JF, Rossi B, Couffignal C, Ruppé E, Chau F, Massias L, Lepeule R, Mentre F, Fantin B
Activity of temocillin in a murine model of urinary tract infection due to Escherichia coli producing or not producing the ESBL CTX-M-15.
The Journal of Antimicrobial Chemotherapy 2015, 70, 1466–1472.
Rossi B, Soubirou J, Chau F, Massias L, Dion S, Lepeule R, Fantin B, Lefort A
Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection.
Antimicrobial Agents and Chemotherapy 2015, 32, 1708.
2014
Lefort A, Chau F, Lepeule R, Dubée V, Kitzis MD, Dion S, Fantin B
Activity of fosfomycin alone or combined with cefoxitin in vitro and in vivo in a murine model of urinary tract infection due to Escherichia coli harbouring CTX-M-15-type extended-spectrum β-lactamase.
International Journal of Antimicrobial Agents 2014, 43, 366-369.
de Lastours V, Bleibtreu A, Chau F, Burdet C, Duval X, Denamur E, Fantin B
Quinolone-resistant Escherichia coli from the faecal microbiota of healthy volunteers after ciprofloxacin exposure are highly adapted to a commensal lifestyle.
The Journal of Antimicrobial Chemotherapy 2014, 69, 761-768.
de Lastours V, Chau F, Roy C, Larroque B, Fantin B
Emergence of quinolone resistance in the microbiota of hospitalized patients treated or not with a fluoroquinolone.
The Journal of Antimicrobial Chemotherapy 2014
Jlili NEH, Réjiba S, Smaoui H, Guillard T, Chau F, Kechrid A, Cambau E
Trend of plasmid-mediated quinolone resistance genes at the Children's Hospital in Tunisia.
Journal of Medical Microbiology 2014, 63, 195-202.
2013
Guillard T, Cambau E, Chau F, Massias L, de Champs C, Fantin B
Ciprofloxacin treatment failure in a murine model of pyelonephritis due to an AAC(6')-Ib-cr-producing Escherichia coli strain susceptible to ciprofloxacin in vitro.
Antimicrobial Agents and Chemotherapy 2013, 57, 5830-5835.
Augustin P, Alsalih G, Launey Y, Delbosc S, Louedec L, Ollivier V, Chau F, Montravers P, Duval X, Michel JB, Meilhac O
Predominant role of host proteases in myocardial damage associated with infectious endocarditis induced by Enterococcus faecalis in a rat model.
Infection and Immunity 2013, 81, 1721–1729.
2012
Ruppe E, Pitsch A, Tubach F, de Lastours V, Chau F, Pasquet B, Lucet JC, Andremont A, Fantin B
Clinical predictive values of extended-spectrum beta-lactamase carriage in patients admitted to medical wards.
European Journal of Clinical Microbiology & Infectious Diseases 2012, 31, 319-325.
Lepeule R, Ruppé E, Le P, Massias L, Chau F, Nucci A, Lefort A, Fantin B
Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.
Antimicrobial Agents and Chemotherapy 2012, 56, 1376-1381.
2009
Fantin B, Duval X, Massias L, Alavoine L, Chau F, Retout S, Andremont A, Mentré F
Ciprofloxacin dosage and emergence of resistance in human commensal bacteria.
The Journal of Infectious Diseases 2009, 200, 390-398.
Allou N, Cambau E, Massias L, Chau F, Fantin B
Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection.
Antimicrobial Agents and Chemotherapy 2009, 53, 4292-4297.
2008
Skurnik D, Bonnet D, Bernède-Bauduin C, Michel R, Guette C, Becker JM, Balaire C, Chau F, Mohler J, Jarlier V, Boutin JP, Moreau B, Guillemot D, Denamur E, Andremont A, Ruimy R
Characteristics of human intestinal Escherichia coli with changing environments.
Environmental Microbiology 2008, 10, 2132-2137.
2004
Lefort A, Arthur M, Depardieu F, Chau F, Pouzet C, Courvalin P, Fantin B
Expression of glycopeptide-resistance gene in response to vancomycin and teicoplanin in the cardiac vegetations of rabbits infected with VanB-type Enterococcus faecalis.
The Journal of Infectious Diseases 2004, 189, 90-97.
